This retrospective analysis of two double-blind, placebo-controlled studies in patients with mild to moderately severe AD investigated the efficacy of rivastigmine 6-12 mg/day on cognitive outcomes in patients with or without the apolipoprotein (APOE) e4 allele. APOE data were collected from patients who consented to pharmacogenetic testing. Treatment differences within each subgroup were compared, using the Observed Case (OC) population. The APOE e4 and non-APOE e4 subgroups comprised 246 and 121 patients, respectively. Overall, APOE e4 noncarriers showed greater decline than carriers (Po0.05). However, at 26 weeks, placebo-treated APOE e4 patients declined 3.04 points below baseline on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), and rivastigmine-treated patients improved by 1.67 points. Non-APOE e4 placebo-treated patients declined by 4.59 points and rivastigmine-treated patients declined by 0.48 points. Thus, non-APOE e4 carriers showed a less favorable course under either placebo or rivastigmine, but both genotype-defined subgroups showed quantitatively similar responses to therapy (both Po0.05 vs placebo).
INTRODUCTION
Alzheimer's disease (AD) is the leading cause of dementia in the elderly, affecting an estimated 4 million patients in the United States alone at a cost of 100 billion dollars a year. 1 Over the past decade, several risk factors have been associated with AD, including genetic background and age. The strongest genetic association in patients with late-onset AD is with apolipoprotein E (APOE) gene polymorphisms. [2] [3] [4] The APOE gene has three major isoforms: e2, e3 and e4, which differ from one another only by single amino-acid substitutions. 3 The possession of at least one e4 allele appears to triple the odds for developing AD. 5, 6 Approximately 60% of late-onset and as many as 92% of early-onset AD cases are reported to carry APOE E4. 7 The specific mechanisms and interactions governing APOE isoform-specific effects in AD are not fully understood, although apolipoprotein E4 has been shown to intensify a number of the disturbances that are characteristic of AD. 3, 4, 8 Of particular clinical interest, considering that the only successful pharmacological treatment of cognitive impairment of AD to date has been the cholinesterase inhibitors, may be the reported interaction between APOE e4 genotype and cholinesterase genotype. 9 It has been proposed that APOE status may be a predictor of treatment response, as demonstrated in a recent independent placebo-controlled study of donepezil, in which a poor response to treatment was observed in APOE e4 carriers. 10 It would be of great clinical value if a patient's genetic profile could be used to predict quantitative or qualitative responses to the cholinesterase inhibitor therapy. This retrospective analysis of two double-blind, placebocontrolled studies in patients with mild to moderately severe AD aimed to evaluate the efficacy of rivastigmine 6-12 mg/day on cognitive outcomes in patients with or without the APOE e4 allele.
METHODS
The full methodologies of the double-blind, placebo-controlled studies have been described previously. 11, 12 Both studies were large, randomized, international, multicentre, double-blind, placebo-controlled, 26-week studies of rivastigmine in patients with mild-to-moderate AD. Informed consent was obtained from all participants. Blood for APOE genotyping was collected from patients entering the studies who gave their consent to pharmacogenetic testing. The primary outcome measure in both studies was the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog).
Patients were stratified into two subgroups, according to APOE status: those carrying at least one APOE e4 allele (ie individuals with genotypes e4/e4, e3/e4 or e2/e4) and non-APOE e4 carriers (e2/e2, e2/e3 or e3/e3). Using these two subgroups, ADAS-cog scores were calculated at baseline and at 26 weeks. Within each subgroup, outcomes in patients receiving placebo or rivastigmine 6-12 mg/day for the study duration were compared using SAS 8.2 statistical software. Analyses were performed using the Observed Case (OC) population, controlling for age and severity with an Analysis of Covariance (ANCOVA) model. The frequencies of adverse events occurring in at least 10% of patients in any subgroup were tabulated.
RESULTS
The APOE e4 and non-APOE e4 subgroups comprised 246 and 121 patients, respectively (Table 1 ). There was a tendency (P ¼ 0.075) for more women to be APOE e4 carriers and more men to be noncarriers. The baseline characteristics and demographics of the genotyped samples of subjects, on whom this study is based, were similar to samples from those who did not consent to pharmacogenetic testing, with both samples having mean ages of 74 years, greater proportions of women than men, and comparable distributions to the treatment groups. Therefore, the subjects included in the current study were representative of the study populations.
Overall (rivastigmine and placebo groups combined), APOE e4 carriers declined by 0.78 points and noncarriers declined by 2.46 points (between-subgroup difference Po0.05, adjusted for baseline score, severity of disease and age) at 26 weeks, compared with baseline. At 26 weeks, placebo-treated APOE e4 patients declined 3.04 ADAS-cog points below baseline and rivastigmine-treated patients improved by 1.67 points. Non-APOE e4 placebo-treated patients declined by 4.59 points and rivastigmine-treated patients declined by only 0.48 (Figure 1 ). Treatment differences (rivastigmine vs placebo) were similar and statistically significant in both subgroups.
The most common adverse events were gastrointestinal, and rivastigmine-treated patients experienced more of these events than placebo-treated patients. Noncarriers experi- enced more nausea under rivastigmine treatment than carriers of the APOE e4 allele ( Table 2) .
DISCUSSION
This was a retrospective study, and the findings are hypothesis-generating, requiring confirmation with prospective studies. The combination of treated and untreated patients for evaluating 'overall' decline is not ideal, but was considered an interesting analysis. There was a tendency for 'overall' APOE e4 noncarriers to have a greater cognitive decline, regardless of whether they were on placebo or on rivastigmine. This tendency was consistent with the trend observed in the two placebo groups, indicating that it has face validity. Importantly, the magnitude of treatment response for each of the rivastigmine groups vs placebo was in the range of 4-5 points. The results suggest that rivastigmine is equally effective across drug-treated groups regardless of genotype, but that there may be a trend towards a greater rate of disease progression in the APOE e4 noncarriers. Similar findings have been reported with galantamine. 13 In contrast, at least one study has suggested that donepezil may be ineffective in APOE e4 carriers. 10 The results add to the already inconsistent database on the relationship between APOE e4 carrier status and drug response. In one study of another cholinesterase inhibitor (galantamine), placebo-treated carriers and noncarriers showed similar cognitive decline over 6 months, 14 while in another similar study carriers showed greater deterioration than noncarriers. 15 A tacrine study that demonstrated less cognitive decline in APOE e4 carriers than in noncarriers, especially in women, over 30 weeks, 16 was consistent with the current 6-month rivastigmine study which shows a tendency for noncarriers taking placebo to have a greater cognitive decline than carriers. The source of these disparate results is not known. However, the latter two studies showing less decline in APOE e4 carriers after disease onset may be more reliable than the former two studies showing similar or greater decline, since the earlier studies did not control for age or severity. Therefore, we would suggest that although APOE e4 hastens the onset of dementia, 3, 4, 7, 8 patients with the allele may progress at a slower rate once the disease process has begun.
Gastrointestinal events, especially nausea and vomiting, are widely known to be the most common side effects of all cholinesterase inhibitors. These events may be minimized by slow titration, but in the studies on which this analysis was based, all patients underwent rapid forced titration schedules, resulting in particularly high incidences of these events. 11, 12 These events tended to be more common in the non-APOE e4 subgroup, despite the fact that doses of rivastigmine reached were similar in both subgroups. The clinical significance of this will need to be investigated in future studies.
Our data demonstrate the importance of placebo when evaluating the differential effectiveness of cholinesterase inhibitor treatment in different subgroups. However, this study is limited by the fact that it is retrospective and because not all patients agreed to undergo pharmacogenetic testing, although the sample of patients on which this study was based were considered representative of the original study populations, based on their comparable baseline characteristics. The patients were representative of those typically included in clinical trials, but they were probably younger than the dementia population in general, increasing the likelihood of including APOE e4 carriers, since the allele accelerates disease onset and greater percentages of early-onset AD cases are reported to carry APOE e4. 7 Our data are therefore not conclusive, but do suggest possible differences, and further investigations would be interesting.
In conclusion, rivastigmine provided important, quantitatively similar benefits in patients with and without the APOE e4 allele. It is possible that APOE status may qualitatively affect the type of treatment response seen, but further studies are required to support the current findings, and to determine the effects of rivastigmine treatment on long-term outcomes in these subgroups. 
